BRPI0510950A - membro de ligação especìfico, composição farmacêutica, método para o tratamento de um tumor em um paciente, uso de um membro de ligação, produtos, ácido nucleico, e, carboidrato de sialiltetraosila - Google Patents
membro de ligação especìfico, composição farmacêutica, método para o tratamento de um tumor em um paciente, uso de um membro de ligação, produtos, ácido nucleico, e, carboidrato de sialiltetraosilaInfo
- Publication number
- BRPI0510950A BRPI0510950A BRPI0510950-7A BRPI0510950A BRPI0510950A BR PI0510950 A BRPI0510950 A BR PI0510950A BR PI0510950 A BRPI0510950 A BR PI0510950A BR PI0510950 A BRPI0510950 A BR PI0510950A
- Authority
- BR
- Brazil
- Prior art keywords
- binding member
- carbohydrate
- tumor
- patient
- products
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
MEMBRO DE LIGAçãO ESPECìFICO, COMPOSIçãO FARMACêUTICA, MéTODO PARA O TRATAMENTO DE UM TUMOR EM UM PACIENTE, USO DE UM MEMBRO DE LIGAçãO, PRODUTOS, áCIDO NUCLéICO, E, CARBOIDRATO DE SIALILTETRAOSILA A presente invenção provê um membro de ligação específico isolado capaz de ligar um carboidrato de sialiltetraosila e diretamente induzir a morte celular sem a necessidade de células efetoras imunes. Este membro de ligação pode ser um anticorpo ou uma parte do mesmo. Também são providos o uso destes membros de ligação em medicina e ácidos nucleicos codificando estes membros de ligação.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0410627.4A GB0410627D0 (en) | 2004-05-12 | 2004-05-12 | Specific binding members |
PCT/GB2005/001805 WO2005108430A2 (en) | 2004-05-12 | 2005-05-11 | Monoclonal antibody sc104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0510950A true BRPI0510950A (pt) | 2007-11-20 |
Family
ID=32526936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0510950-7A BRPI0510950A (pt) | 2004-05-12 | 2005-05-11 | membro de ligação especìfico, composição farmacêutica, método para o tratamento de um tumor em um paciente, uso de um membro de ligação, produtos, ácido nucleico, e, carboidrato de sialiltetraosila |
Country Status (17)
Country | Link |
---|---|
US (2) | US7915387B2 (pt) |
EP (3) | EP1745077B1 (pt) |
JP (2) | JP4944016B2 (pt) |
KR (1) | KR101213282B1 (pt) |
CN (1) | CN1961004B (pt) |
AU (2) | AU2005240837B2 (pt) |
BR (1) | BRPI0510950A (pt) |
CA (1) | CA2563516C (pt) |
ES (1) | ES2400571T3 (pt) |
GB (1) | GB0410627D0 (pt) |
HK (1) | HK1101696A1 (pt) |
IL (1) | IL178791A (pt) |
MX (1) | MXPA06012955A (pt) |
NO (1) | NO20065651L (pt) |
NZ (3) | NZ589214A (pt) |
WO (1) | WO2005108430A2 (pt) |
ZA (1) | ZA200609365B (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0410627D0 (en) * | 2004-05-12 | 2004-06-16 | Scancell Ltd | Specific binding members |
SG173577A1 (en) * | 2009-03-16 | 2011-09-29 | Cephalon Australia Pty Ltd | Humanised antibodies with anti-tumour activity |
KR20120104558A (ko) | 2009-11-05 | 2012-09-21 | 세파론 오스트레일리아 피티와이 엘티디 | 돌연변이형 kras 또는 braf 유전자를 포함하는 암을 치료하는 방법 |
ES2865068T3 (es) | 2011-01-14 | 2021-10-14 | Univ California | Anticuerpos terapéuticos contra la proteína ROR-1 y métodos para usarlos |
GB201319374D0 (en) | 2013-11-01 | 2013-12-18 | Univ Nottingham | Glycans as functional cancer targets abd antibodies thereto |
ES2924393T3 (es) * | 2014-04-16 | 2022-10-06 | Inst Nat Sante Rech Med | Anticuerpos para la prevención o el tratamiento de episodios hemorrágicos |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
AU7757581A (en) | 1980-11-19 | 1982-05-27 | United Energy Technologies Inc. | Enhanced surface tubing |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
JPS5811808A (ja) | 1981-07-16 | 1983-01-22 | Niles Parts Co Ltd | 方位検出表示回路 |
DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
WO1984004642A1 (en) | 1983-05-09 | 1984-11-22 | Gen Electric Co Plc | Cathode ray tube display device |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
JP3854306B2 (ja) * | 1991-03-06 | 2006-12-06 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | ヒト化及びキメラモノクローナル抗体 |
RU2139351C1 (ru) * | 1991-04-25 | 1999-10-10 | Чугаи Сейяку Кабусики Кайся | Н- и l-цепи моноклонального антитела рм1 (монат) к рецептору il-6r человека и их v-области, модифицированная монат, его н- и l-цепи и их v-области, cdr- последовательности, днк-последовательности |
DE4118120A1 (de) * | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
WO1994013804A1 (en) | 1992-12-04 | 1994-06-23 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
PT699237E (pt) * | 1994-03-17 | 2003-07-31 | Merck Patent Gmbh | Fvs de cadeia anti-egfr e anticorpos anti-egfr |
JPH09173063A (ja) | 1995-12-26 | 1997-07-08 | Cosmo Sogo Kenkyusho:Kk | 抗ヒトリポタンパク質(a)モノクローナル抗体可変領域のDNA塩基配列およびアミノ酸配列 |
WO1997034634A1 (en) * | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
US5994511A (en) * | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
US6350860B1 (en) | 1997-08-18 | 2002-02-26 | Innogenetics N.V. | Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders |
ATE446317T1 (de) | 2001-05-11 | 2009-11-15 | Ludwig Inst For Cancer Res Ltd | Spezifische bindungsproteine und ihre verwendung |
GB0410627D0 (en) * | 2004-05-12 | 2004-06-16 | Scancell Ltd | Specific binding members |
US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
-
2004
- 2004-05-12 GB GBGB0410627.4A patent/GB0410627D0/en not_active Ceased
-
2005
- 2005-05-11 JP JP2007512338A patent/JP4944016B2/ja not_active Expired - Fee Related
- 2005-05-11 CA CA2563516A patent/CA2563516C/en not_active Expired - Fee Related
- 2005-05-11 EP EP05742378A patent/EP1745077B1/en not_active Not-in-force
- 2005-05-11 NZ NZ589214A patent/NZ589214A/en not_active IP Right Cessation
- 2005-05-11 AU AU2005240837A patent/AU2005240837B2/en not_active Ceased
- 2005-05-11 EP EP11167425A patent/EP2397500A1/en not_active Withdrawn
- 2005-05-11 ES ES05742378T patent/ES2400571T3/es active Active
- 2005-05-11 NZ NZ593171A patent/NZ593171A/xx not_active IP Right Cessation
- 2005-05-11 BR BRPI0510950-7A patent/BRPI0510950A/pt not_active IP Right Cessation
- 2005-05-11 EP EP11167406A patent/EP2392598A1/en not_active Withdrawn
- 2005-05-11 CN CN2005800153237A patent/CN1961004B/zh not_active Expired - Fee Related
- 2005-05-11 NZ NZ550738A patent/NZ550738A/en not_active IP Right Cessation
- 2005-05-11 MX MXPA06012955A patent/MXPA06012955A/es active IP Right Grant
- 2005-05-11 US US11/596,501 patent/US7915387B2/en not_active Expired - Fee Related
- 2005-05-11 WO PCT/GB2005/001805 patent/WO2005108430A2/en active Application Filing
-
2006
- 2006-10-22 IL IL178791A patent/IL178791A/en not_active IP Right Cessation
- 2006-11-10 ZA ZA200609365A patent/ZA200609365B/xx unknown
- 2006-12-07 NO NO20065651A patent/NO20065651L/no not_active Application Discontinuation
- 2006-12-12 KR KR1020067026167A patent/KR101213282B1/ko not_active IP Right Cessation
-
2007
- 2007-06-20 HK HK07106570.8A patent/HK1101696A1/xx not_active IP Right Cessation
-
2011
- 2011-02-03 US US13/020,387 patent/US8343490B2/en not_active Expired - Fee Related
- 2011-02-04 AU AU2011200487A patent/AU2011200487B2/en not_active Ceased
- 2011-12-28 JP JP2011288606A patent/JP2012105654A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0510950A (pt) | membro de ligação especìfico, composição farmacêutica, método para o tratamento de um tumor em um paciente, uso de um membro de ligação, produtos, ácido nucleico, e, carboidrato de sialiltetraosila | |
WO2001000828A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
BR9912653A (pt) | Vìrus de herpes atenuado, cepa de vìrus, célula dendrìtica, processo para produzir um célula, composição farmacêutica, uso de um vìrus, e, processo para executar a terapia de gene em um paciente humano ou animal ou para tratar ou prevenir uma infecção patogênica ou câncer para tratar paciente animal | |
CY1112110T1 (el) | Κυκλικο μοριο dna το οποιο διαθετει μια συμβατικη αφετηρια αντιγραφης, η διαδικασια παρασκευης του και η χρηση του στην γονιδιακη θεραπεια | |
EA201301072A1 (ru) | Антитела против il-23p19 и их применение | |
WO2005094554A3 (en) | Therapeutic agents, methods, and treatments | |
WO2000060077A3 (en) | Compounds for therapy and diagnosis of lung cancer and methods for their use | |
WO2000060076A3 (en) | Compositions for the treatment and diagnosis of breast cancer and methods for their use | |
BR112012012160A2 (pt) | material e métodos para tratar ou prevenir doenças associadas ao her-3 | |
MX2007007033A (es) | Estreptococus del grupo b. | |
HUP0400231A2 (hu) | Rákos megbetegedések kezelésében különösen hasznos, immundecepcióra szolgáló eljárások és gyógyszerkészítmények | |
WO2001072295A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
IL187321A (en) | Molecules that have a specific link to a surrogate cell that encode monoclonal antibodies capable of neutralizing viruses, medicinal preparations containing them, and their uses in drug preparation | |
BR0214840A (pt) | Genes | |
WO2002092001A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
Krukemeyer et al. | Magnetic drug targeting in a rhabdomyosarcoma rat model using magnetite-dextran composite nanoparticle-bound mitoxantrone and 0.6 tesla extracorporeal magnets− sarcoma treatment in progress | |
DE10290072D2 (de) | Modulare Transfektionssysteme | |
WO2003029429A3 (en) | Traversal of nucleic acid molecules through a fluid space and expression in repair cells | |
Zhu et al. | Recent advances of nanotechnology-facilitated bacteria-based drug and gene delivery systems for cancer treatment | |
DE60132443D1 (de) | In lebenden zielzellen | |
NO20051159L (no) | Preparater og fremgangsmater for behandling av sykdommer som viser feilsammensetting av aggregering av protein | |
Jia et al. | Microneedles loaded with glutathione‐scavenging composites for nitric oxide enhanced photodynamic therapy of melanoma | |
WO2006122971A3 (en) | Treatment of disease using an improved regulated expression system | |
BR0111024A (pt) | Composições e métodos para a terapia e diagnóstico de câncer de mama | |
DE60229363D1 (de) | Monozyte-spezifisches teilchenförmiges verabreichungsvehikel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: ARANA THERAPEUTICS LIMITED (AU) Free format text: TRANSFERIDO DE: SCANCELL LIMITED |
|
B25D | Requested change of name of applicant approved |
Owner name: ARANA THERAPEUTICS PTY LTD. (AU) Free format text: NOME ALTERADO DE: ARANA THERAPEUTICS LIMITED |
|
B25D | Requested change of name of applicant approved |
Owner name: CEPHALON AUSTRALIA PTY LTD. (AU) Free format text: NOME ALTERADO DE: ARANA THERAPEUTICS PTY LTD. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |